Design of Chimeric GLP-1A Using Oligomeric Bile Acids to Utilize Transporter-mediated Endocytosis for Oral Delivery

Overview

Journal Biomater Res

Specialty Biomedical Engineering

Date 2023 Sep 2

PMID 37660070

Authors

Seho Kweon

Jun-Hyuck Lee

Seong-Bin Yang

Seong Jin Park

Laxman Subedi

Jung-Hyun Shim

Seung-Sik Cho

Jeong Uk Choi

Youngro Byun

Jooho Park

Jin Woo Park

Affiliations

Soon will be listed here.

Abstract

Background: Despite the effectiveness of glucagon-like peptide-1 agonist (GLP-1A) in the treatment of diabetes, its large molecular weight and high hydrophilicity result in poor cellular permeability, thus limiting its oral bioavailability. To address this, we developed a chimeric GLP-1A that targets transporter-mediated endocytosis to enhance cellular permeability to GLP-1A by utilizing the transporters available in the intestine, particularly the apical sodium-dependent bile acid transporter (ASBT).

Methods: In silico molecular docking and molecular dynamics simulations were used to investigate the binding interactions of mono-, bis-, and tetra-deoxycholic acid (DOCA) (monoDOCA, bisDOCA, and tetraDOCA) with ASBT. After synthesizing the chimeric GLP-1A-conjugated oligomeric DOCAs (mD-G1A, bD-G1A, and tD-G1A) using a maleimide reaction, in vitro cellular permeability and insulinotropic effects were assessed. Furthermore, in vivo oral absorption in rats and hypoglycemic effect on diabetic db/db mice model were evaluated.

Results: In silico results showed that tetraDOCA had the lowest interaction energy, indicating high binding affinity to ASBT. Insulinotropic effects of GLP-1A-conjugated oligomeric DOCAs were not different from those of GLP-1A-Cys or exenatide. Moreover, bD-G1A and tD-G1A exhibited improved in vitro Caco-2 cellular permeability and showed higher in vivo bioavailability (7.58% and 8.63%) after oral administration. Regarding hypoglycemic effects on db/db mice, tD-G1A (50 μg/kg) lowered the glucose level more than bD-G1A (50 μg/kg) compared with the control (35.5% vs. 26.4%).

Conclusion: GLP-1A was conjugated with oligomeric DOCAs, and the resulting chimeric compound showed the potential not only for glucagon-like peptide-1 receptor agonist activity but also for oral delivery. These findings suggest that oligomeric DOCAs can be used as effective carriers for oral delivery of GLP-1A, offering a promising solution for enhancing its oral bioavailability and improving diabetes treatment.

References

Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden D . Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C). Pharmaceutics. 2019; 11(2). PMC: 6410172. DOI: 10.3390/pharmaceutics11020078. View

Li X, Liu Z, Xu S, Ma X, Zhao Z, Hu H . A drug delivery system constructed by a fusion peptide capturing exosomes targets to titanium implants accurately resulting the enhancement of osseointegration peri-implant. Biomater Res. 2022; 26(1):89. PMC: 9795642. DOI: 10.1186/s40824-022-00331-0. View

Yao Z, Jiang X, Yao H, Wu Y, Zhang F, Wang C . Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs. Biomater Res. 2022; 26(1):71. PMC: 9717509. DOI: 10.1186/s40824-022-00309-y. View

Pechenov S, Revell J, Will S, Naylor J, Tyagi P, Patel C . Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Sci Rep. 2021; 11(1):22521. PMC: 8602401. DOI: 10.1038/s41598-021-01750-0. View

Marathe P, Gao H, Close K . American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017; 9(4):320-324. DOI: 10.1111/1753-0407.12524. View

Drucker D . Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. View

Yu M, Benjamin M, Srinivasan S, Morin E, Shishatskaya E, Schwendeman S . Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018; 130:113-130. PMC: 6843995. DOI: 10.1016/j.addr.2018.07.009. View

Park J, Jeon O, Yun J, Nam H, Hwang J, Al-Hilal T . End-Site-Specific Conjugation of Enoxaparin and Tetradeoxycholic Acid Using Nonenzymatic Glycosylation for Oral Delivery. J Med Chem. 2016; 59(23):10520-10529. DOI: 10.1021/acs.jmedchem.6b00936. View

Abramson A, Caffarel-Salvador E, Khang M, Dellal D, Silverstein D, Gao Y . An ingestible self-orienting system for oral delivery of macromolecules. Science. 2019; 363(6427):611-615. PMC: 6430586. DOI: 10.1126/science.aau2277. View

10.

Heller S, Peyrot M, Oates S, Taylor A . Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7299018. DOI: 10.1136/bmjdrc-2020-001194. View

11.

Zhang X, Chen G, Fu X, Wang Y, Zhao Y . Magneto-Responsive Microneedle Robots for Intestinal Macromolecule Delivery. Adv Mater. 2021; 33(44):e2104932. DOI: 10.1002/adma.202104932. View

12.

Cullen P, Steinberg F . To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat Rev Mol Cell Biol. 2018; 19(11):679-696. DOI: 10.1038/s41580-018-0053-7. View

13.

Bech E, Pedersen S, Jensen K . Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. ACS Med Chem Lett. 2018; 9(7):577-580. PMC: 6047018. DOI: 10.1021/acsmedchemlett.8b00226. View

14.

Fremaux J, Venin C, Mauran L, Zimmer R, Guichard G, Goudreau S . Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo. Nat Commun. 2019; 10(1):924. PMC: 6389962. DOI: 10.1038/s41467-019-08793-y. View

15.

Deng F, Kim K, Moon J, Bae Y . Bile Acid Conjugation on Solid Nanoparticles Enhances ASBT-Mediated Endocytosis and Chylomicron Pathway but Weakens the Transcytosis by Inducing Transport Flow in a Cellular Negative Feedback Loop. Adv Sci (Weinh). 2022; 9(21):e2201414. PMC: 9313510. DOI: 10.1002/advs.202201414. View

16.

Scheen A, Paquot N . Obesity. A new paradigm for treating obesity and diabetes mellitus. Nat Rev Endocrinol. 2015; 11(4):196-8. DOI: 10.1038/nrendo.2015.3. View

17.

Tschop M, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Muller T . Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metab. 2016; 24(1):51-62. DOI: 10.1016/j.cmet.2016.06.021. View

18.

Tyagi P, Pechenov S, Subramony J . Oral peptide delivery: Translational challenges due to physiological effects. J Control Release. 2018; 287:167-176. DOI: 10.1016/j.jconrel.2018.08.032. View

19.

Deng F, Bae Y . Lipid raft-mediated and upregulated coordination pathways assist transport of glycocholic acid-modified nanoparticle in a human breast cancer cell line of SK-BR-3. Int J Pharm. 2022; 617:121589. PMC: 8996487. DOI: 10.1016/j.ijpharm.2022.121589. View

20.

El-Sayed N, Shirazi A, El-Meligy M, El-Ziaty A, Nagieb Z, Parang K . Design, synthesis, and evaluation of chitosan conjugated GGRGDSK peptides as a cancer cell-targeting molecular transporter. Int J Biol Macromol. 2016; 87:611-22. DOI: 10.1016/j.ijbiomac.2016.03.020. View